Gastrointestinal (GI): NSAIDs that block COX-one action have correlations with GI problems due to inhibition with the synthesis of gastroprotective brokers like PGE2 and also other prostaglandins. This inhibition leads to lowered mucin production by gastric epithelial cells, considerably less bicarbonate secretion, and fewer epithelial mobile turnover, amid other steps. https://brians258zxu6.blue-blogs.com/profile